EMA’s Revised ATMP Evaluation Procedure Gets Industry Thumbs Up
Executive Summary
EU pharmaceutical companies believe the revisions the European Medicines Agency has made to its procedure for evaluating gene and cell therapy products addresses the specific needs of advanced therapy developers. They have also welcomed, in principle, a revised EMA guideline on the follow-up and risk management of such products.
You may also be interested in...
Industry Welcomes EU Action Plan To Boost ATMP Development
An action plan produced by the European Medicines Agency and the European Commission has put forward a number of ideas for streamlining the processes for developing and assessing advanced therapy medicines, with the aim of speeding up the current sluggish rate of ATMP approvals. Industry says it will assess the proposals to see how well they address the key issues worrying the sector.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.